Epigenetic Modulators and the New Immunotherapies.

The New England journal of medicine 20160218

The Effects of Class-Specific Histone Deacetylase Inhibitors on the Development of Limbs During Organogenesis.

Toxicological sciences : an official journal of the Society of Toxicology 20151101

Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function.

Nucleic acids research 20150420

Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.

Chemistry & biology 20150219

A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors.

Archives of toxicology 20150101

Histone deacetylase 4 promotes ubiquitin-dependent proteasomal degradation of Sp3 in SH-SY5Y cells treated with di(2-ethylhexyl)phthalate (DEHP), determining neuronal death.

Toxicology and applied pharmacology 20141001

Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells.

PloS one 20140101

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters 20130801

The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.

Bioorganic & medicinal chemistry letters 20121201

A combined approach for the study of histone deacetylase inhibitors.

Molecular bioSystems 20121101

Histone deacetylase inhibitors preserve function in aging axons.

Journal of neurochemistry 20121101

Novel agents in Hodgkin lymphoma.

Current oncology reports 20121001

P300/CBP associated factor regulates nitroglycerin-dependent arterial relaxation by N(ε)-lysine acetylation of contractile proteins.

Arteriosclerosis, thrombosis, and vascular biology 20121001

MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.

European journal of pharmacology 20120915

Effect of valproic acid on mitochondrial epigenetics.

European journal of pharmacology 20120905

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.

Nature neuroscience 20120901

Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction.

Journal of chemical information and modeling 20120827

P38 MAP kinase functions as a switch in MS-275-induced reactive oxygen species-dependent autophagy and apoptosis in human colon cancer cells.

Free radical biology & medicine 20120801

Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.

Bioorganic & medicinal chemistry 20120715

Increased neuron specific enolase expression by urothelial cells exposed to or malignantly transformed by exposure to Cd²⁺ or As³⁺.

Toxicology letters 20120707

Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3.

Journal of cellular and molecular medicine 20120701

Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.

European journal of medicinal chemistry 20120701

Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.

The Journal of clinical endocrinology and metabolism 20120701

Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis.

Chemistry & biology 20120622

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120620

Antitumor activity of Chidamide in hepatocellular carcinoma cell lines.

Molecular medicine reports 20120601

HDAC1 regulates fear extinction in mice.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20120411

Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex.

Brain research 20120404

Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.

Circulation research 20120302

Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.

Bioorganic & medicinal chemistry letters 20120301

[Histone deacetylase inhibitor MS-275 treatment alters immune molecule content and categories in hepatocarcinoma exosomes].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20120301

Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.

Blood 20120202

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

Investigational new drugs 20120201

Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.

Neuro-oncology 20120201

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.

British journal of cancer 20120103

HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis.

The Prostate 20120101

Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-γ.

PLoS pathogens 20120101

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

PloS one 20120101

Loss of deacetylation activity of Hdac6 affects emotional behavior in mice.

PloS one 20120101

Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation.

Scientific reports 20120101

Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers.

PloS one 20120101

Novel therapies for aggressive B-cell lymphoma.

Advances in hematology 20120101

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.

OncoTargets and therapy 20120101

A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.

ChemMedChem 20111209

Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.

Journal of cellular physiology 20111201

Histone deacetylase inhibitors and periodontal bone loss.

Journal of periodontal research 20111201

Raman microspectroscopy detects epigenetic modifications in living Jurkat leukemic cells.

Epigenomics 20111201

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.

Cancer discovery 20111201

The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.

Bioorganic & medicinal chemistry letters 20111015

The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.

Experimental hematology 20111001

Entinostat for treatment of solid tumors and hematologic malignancies.

Expert opinion on investigational drugs 20111001

Histone deacetylase inhibitor MS-275 stimulates bone formation in part by enhancing Dhx36-mediated TNAP transcription.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110901

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.

Cancer chemotherapy and pharmacology 20110901

Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells.

The Journal of biological chemistry 20110826

Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.

World journal of gastroenterology 20110821

Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.

Bioorganic & medicinal chemistry letters 20110815

Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.

Cancer 20110801

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

Cancer letters 20110801

Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition.

Brain : a journal of neurology 20110801

A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.

Bioorganic & medicinal chemistry letters 20110715

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.

Journal of medicinal chemistry 20110714

The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.

Oncogene 20110707

Aromatase inhibitors and xenograft studies.

Steroids 20110701

Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.

Leukemia research 20110701

Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275.

Anti-cancer drugs 20110701

Epigenetic profiling of the antitumor natural product psammaplin A and its analogues.

Bioorganic & medicinal chemistry 20110615

Analysis of the GAD1 promoter: trans-acting factors and DNA methylation converge on the 5' untranslated region.

Neuropharmacology 20110601

Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons.

Neuropharmacology 20110601

Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory.

Learning & memory (Cold Spring Harbor, N.Y.) 20110601

Clinical development of panobinostat in classical Hodgkin's lymphoma.

Expert review of hematology 20110601

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition.

Neuroscience letters 20110415

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.

Cancer research 20110301

[Design, synthesis, and biological activities of histone deacetylase inhibitors with diketo ester as zinc binding group].

Yao xue xue bao = Acta pharmaceutica Sinica 20110301

Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis.

The Journal of biological chemistry 20110211

DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.

Journal of Korean medical science 20110201

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.

Cancer research 20110115

Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases.

Molecular pharmacology 20110101

Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.

Bioorganic & medicinal chemistry letters 20110101

Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.

Journal of biomedicine & biotechnology 20110101

Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?

Journal of biomedicine & biotechnology 20110101

Differences in the epigenetic regulation of MT-3 gene expression between parental and Cd+2 or As+3 transformed human urothelial cells.

Cancer cell international 20110101

Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth.

Molecular cancer 20110101

Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications.

BMC medicine 20110101

Interpreting clinical assays for histone deacetylase inhibitors.

Cancer management and research 20110101

Myelodysplastic syndrome and histone deacetylase inhibitors: 'to be or not to be acetylated'?

Journal of biomedicine & biotechnology 20110101

Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.

Journal of biomedicine & biotechnology 20110101

Epigenetics in breast cancer: what's new?

Breast cancer research : BCR 20110101

Epigenetics in prostate cancer.

Prostate cancer 20110101

Romidepsin in the treatment of cutaneous T-cell lymphoma.

Journal of blood medicine 20110101

Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.

European journal of nuclear medicine and molecular imaging 20101201

Inhibitors selective for HDAC6 in enzymes and cells.

Bioorganic & medicinal chemistry letters 20101201

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.

Molecular cancer therapeutics 20101201

The DAC system and associations with multiple myeloma.

Investigational new drugs 20101201

Histone deacetylase inhibitors in Hodgkin lymphoma.

Investigational new drugs 20101201

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.

Investigational new drugs 20101201

Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells.

Journal of cellular physiology 20101101

Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.

Autophagy 20101101

Histone deacetylase inhibitors in the treatment of lymphoma.

Discovery medicine 20101101

Absence of Metallothionein 3 Expression in Breast Cancer is a Rare, But Favorable Marker of Outcome that is Under Epigenetic Control.

Toxicological and environmental chemistry 20101001

Histone deacetylase inhibitors in lymphoma.

Current opinion in oncology 20100901

MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis.

Neuroscience 20100811

Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells.

Rheumatology (Oxford, England) 20100801

American Society of Clinical Oncology--46th annual meeting.

IDrugs : the investigational drugs journal 20100801

Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.

Journal of medicinal chemistry 20100624

New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.

Bioorganic & medicinal chemistry 20100601

Epigenetic therapy of lymphoma using histone deacetylase inhibitors.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100601

[Histone acetylation, gene regulation and depression].

Medecine sciences : M/S 20100501

Chemical phylogenetics of histone deacetylases.

Nature chemical biology 20100301

MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.

European journal of pharmacology 20100210

Induction of TAp63 by histone deacetylase inhibitors.

Biochemical and biophysical research communications 20100122

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.

Oncogene 20100107

Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells.

Urologic oncology 20100101

HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity.

Oncology reports 20100101

Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.

Nature chemical biology 20100101

Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils.

Journal of inflammation (London, England) 20100101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100101

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.

PloS one 20100101

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

OncoTargets and therapy 20100101

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.

OncoTargets and therapy 20100101

Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome.

PloS one 20100101

New treatments for myelodysplastic syndromes.

Mediterranean journal of hematology and infectious diseases 20100101

Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201

Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms.

Molecular pharmacology 20091101

HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.

Cancer research 20091101

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.

Blood 20091015

Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.

International journal of oncology 20091001

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

Blood 20090924

HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.

Biochemical and biophysical research communications 20090918

Antidepressant actions of histone deacetylase inhibitors.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20090916

Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

Oncogene 20090903

Epigenetic influences on sensory regeneration: histone deacetylases regulate supporting cell proliferation in the avian utricle.

Journal of the Association for Research in Otolaryngology : JARO 20090901

Lysine acetylation targets protein complexes and co-regulates major cellular functions.

Science (New York, N.Y.) 20090814

Recent advances in the development of polyamine analogues as antitumor agents.

Journal of medicinal chemistry 20090813

Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.

Journal of neuro-oncology 20090701

DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation.

Stem cells (Dayton, Ohio) 20090701

Epigenetic modifiers: basic understanding and clinical development.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

Clinical studies of histone deacetylase inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.

Journal of medicinal chemistry 20090611

Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells.

Stem cells and development 20090501

Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain.

Molecular pharmacology 20090501

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.

Haematologica 20090501

[MS-275, a histone deacetylase inhibitor, induces apoptosis and alters survivin gene expression in human myeloma cell line U266].

Ai zheng = Aizheng = Chinese journal of cancer 20090501

Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.

Journal of medicinal chemistry 20090423

[Effects of histone deacetylase inhibitor MS-275 on expression of survivin and NF-kappaB in the human myeloma cell line U266 cells].

Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090401

Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives.

Bioorganic & medicinal chemistry 20090315

Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor.

Biological & pharmaceutical bulletin 20090301

N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1).

Bioorganic & medicinal chemistry letters 20090215

Histone acetylation resulting in resistance to methotrexate in choroid plexus cells.

Journal of neuro-oncology 20090201

The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes.

Molecular pharmacology 20090201

Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090115

Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors.

Cellular immunology 20090101

'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.

Retrovirology 20090101

Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.

PloS one 20090101

Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.

International journal of cancer 20081215

Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.

Leukemia 20081201

The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines.

Oncology reports 20081101

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.

Leukemia research 20080901

Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation.

Analytical chemistry 20080815

Sp1-mediated TRAIL induction in chemosensitization.

Cancer research 20080815

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.

Melanoma research 20080801

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080715

Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.

Leukemia 20080701

p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage.

Oncogene 20080605

Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.

Molecular cancer therapeutics 20080601

Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080515

Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells.

Leukemia research 20080501

Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.

Bioorganic & medicinal chemistry letters 20080415

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours.

British journal of cancer 20080408

Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.

Journal of molecular graphics & modelling 20080401

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.

Bioorganic & medicinal chemistry 20080315

Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.

Bioorganic & medicinal chemistry letters 20080315

Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.

Leukemia 20080301

Histone deacetylase inhibitors in lymphoma and solid malignancies.

Expert review of anticancer therapy 20080301

Regulation of arginase-1 expression in macrophages by a protein kinase A type I and histone deacetylase dependent pathway.

Journal of cellular biochemistry 20080201

Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB.

Leukemia research 20080201

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

The Biochemical journal 20080115

Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.

Bioorganic & medicinal chemistry letters 20071115

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.

Journal of medicinal chemistry 20071115

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Journal of cancer research and clinical oncology 20071101

Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.

The Journal of biological chemistry 20070928

Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.

World journal of gastroenterology 20070907

Trithiocarbonates: exploration of a new head group for HDAC inhibitors.

Bioorganic & medicinal chemistry letters 20070901

Relationship between embryonic histonic hyperacetylation and axial skeletal defects in mouse exposed to the three HDAC inhibitors apicidin, MS-275, and sodium butyrate.

Toxicological sciences : an official journal of the Society of Toxicology 20070801

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.

The Prostate 20070801

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070701

Bispyridinium dienes: histone deacetylase inhibitors with selective activities.

Journal of medicinal chemistry 20070517

MAGE-A9 mRNA and protein expression in bladder cancer.

International journal of cancer 20070515

Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.

Bioorganic & medicinal chemistry letters 20070415

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

Blood 20070401

Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

British journal of pharmacology 20070401

The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.

Cancer gene therapy 20070301

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.

Journal of pharmaceutical and biomedical analysis 20070117

Measuring cytotoxicity: a new perspective on LC50.

Anticancer research 20070101

MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.

The international journal of biochemistry & cell biology 20070101

HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.

The international journal of biochemistry & cell biology 20070101

Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.

Endocrine-related cancer 20061201

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Investigational new drugs 20060901

Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.

Bioorganic & medicinal chemistry letters 20060801

Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases.

Acta neuropathologica 20060801

Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.

Molecular cancer therapeutics 20060501

Curcumin is an inhibitor of p300 histone acetylatransferase.

Medicinal chemistry (Shariqah (United Arab Emirates)) 20060301

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.

Cancer chemotherapy and pharmacology 20060201

Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells.

Anticancer research 20060101

Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.

Journal of molecular neuroscience : MN 20060101

Histone deacetylase inhibitors in cancer therapy.

Cancer investigation 20060101

Histone deacetylase inhibitors promote osteoblast maturation.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051201

Targeting epigenetic changes in acute myeloid leukemia.

Clinical advances in hematology & oncology : H&O 20051101

Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.

Clinical prostate cancer 20050901

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.

Molecular and cellular biology 20050701

[A new target of cancer therapy: advances in the study of histone deacetylase].

Yao xue xue bao = Acta pharmaceutica Sinica 20050701

In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.

The Prostate 20050615

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050610

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050501

Histone deacetylase inhibitors and cancer: from cell biology to the clinic.

European journal of cell biology 20050301

Peak shape improvement of basic analytes in capillary liquid chromatography.

Journal of separation science 20050201

Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.

Annals of clinical and laboratory science 20050101

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040915

Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.

Cancer biology & therapy 20040801

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.

Leukemia 20040701

Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells.

International journal of cancer 20040610

Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040525

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

Cancer research 20040401

(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.

Bioorganic & medicinal chemistry letters 20040105

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

Cancer research 20040101

Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.

Journal of medicinal chemistry 20031218

Identification of novel isoform-selective inhibitors within class I histone deacetylases.

The Journal of pharmacology and experimental therapeutics 20031101

Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.

Oncogene 20030918

The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

Cancer research 20030701

Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.

Blood 20030301

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.

Molecular cancer therapeutics 20030201

Trifluoromethyl ketones as inhibitors of histone deacetylase.

Bioorganic & medicinal chemistry letters 20021202

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.

Cancer research 20021101

Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.

Cancer research 20020801

Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group.

Bioorganic & medicinal chemistry letters 20020520

Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.

The Journal of biological chemistry 20020215

MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.

Cancer research 20010201